US6312700B1
(en)
*
|
1998-02-24 |
2001-11-06 |
Andrew D. Weinberg |
Method for enhancing an antigen specific immune response with OX-40L
|
TWI476001B
(zh)
|
2011-12-26 |
2015-03-11 |
Ind Tech Res Inst |
三倍體Fc融合蛋白及其用途
|
CN104520321A
(zh)
|
2012-01-09 |
2015-04-15 |
斯克利普斯研究所 |
超长互补决定区及其用途
|
EP2806883B1
(en)
|
2012-01-25 |
2019-04-24 |
DNAtrix, Inc. |
Biomarkers and combination therapies using oncolytic virus and immunomodulation
|
WO2013119202A1
(en)
|
2012-02-06 |
2013-08-15 |
Providence Health & Services - Oregon |
Cancer treatment and monitoring methods using ox40 agonists
|
US10329350B2
(en)
|
2012-12-26 |
2019-06-25 |
Industrial Technology Research Institute |
Method for producing a multivalent fab fragment with collagen-like peptide
|
US9644021B2
(en)
|
2013-01-11 |
2017-05-09 |
The California Institute For Biomedical Research |
Bovine fusion antibodies
|
WO2014121099A1
(en)
*
|
2013-01-31 |
2014-08-07 |
Thomas Jefferson University |
Agonist fusion protein for cd40 ox40 and uses thereof
|
US9834610B2
(en)
|
2013-01-31 |
2017-12-05 |
Thomas Jefferson University |
Fusion proteins for modulating regulatory and effector T cells
|
WO2015116178A1
(en)
*
|
2014-01-31 |
2015-08-06 |
Thomas Jefferson University |
Fusion proteins for modulating regulatory and effector t cells
|
MX2015010880A
(es)
|
2013-02-22 |
2015-12-03 |
Curevac Gmbh |
Combinacion de vacunacion e inhibicion de la trayectoria pd-1.
|
US9546203B2
(en)
*
|
2013-03-14 |
2017-01-17 |
Amgen Inc. |
Aglycosylated Fc-containing polypeptides with cysteine substitutions
|
AU2014233114B2
(en)
|
2013-03-15 |
2018-03-08 |
Richard S. Kornbluth |
Composition comprised of antigen linked to a TNF SuperFamily ligand
|
US20160237156A1
(en)
|
2013-07-11 |
2016-08-18 |
The California Institute For Biomedical Research |
Immunoglobulin fusion proteins and compositions thereof
|
US20150038682A1
(en)
*
|
2013-08-02 |
2015-02-05 |
Jn Biosciences Llc |
Antibodies or fusion proteins multimerized via homomultimerizing peptide
|
EP3653714A1
(en)
|
2013-11-22 |
2020-05-20 |
DNAtrix, Inc. |
Adenovirus expressing immune cell stimulatory receptor agonist(s)
|
CN106102774A
(zh)
|
2013-12-17 |
2016-11-09 |
豪夫迈·罗氏有限公司 |
包含ox40结合激动剂和pd‑1轴结合拮抗剂的组合疗法
|
WO2015135558A1
(en)
|
2014-03-12 |
2015-09-17 |
Curevac Gmbh |
Combination of vaccination and ox40 agonists
|
MX2016012779A
(es)
|
2014-03-31 |
2017-04-27 |
Genentech Inc |
Terapia de combinacion con agentes antiangiogénesis y agonistas de unión a ox40.
|
SG11201608181YA
(en)
|
2014-04-03 |
2016-10-28 |
Augusta University Res Inst Inc |
Methods for enhancing the efficacy of a tumor-directed immune response
|
CN106456734A
(zh)
*
|
2014-05-29 |
2017-02-22 |
免疫医疗有限责任公司 |
Ox40l融合蛋白及其用途
|
AU2015287773B2
(en)
|
2014-07-11 |
2018-03-29 |
Gilead Sciences, Inc. |
Modulators of toll-like receptors for the treatment of HIV
|
MA41044A
(fr)
|
2014-10-08 |
2017-08-15 |
Novartis Ag |
Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
|
TW201619200A
(zh)
|
2014-10-10 |
2016-06-01 |
麥迪紐有限責任公司 |
人類化抗-ox40抗體及其用途
|
TWI716362B
(zh)
|
2014-10-14 |
2021-01-21 |
瑞士商諾華公司 |
針對pd-l1之抗體分子及其用途
|
SG11201703219WA
(en)
|
2014-10-24 |
2017-05-30 |
Astrazeneca Ab |
Combination
|
MX2017005751A
(es)
|
2014-11-03 |
2018-04-10 |
Genentech Inc |
Métodos y biomarcadores para predecir la eficacia y evaluación de un tratamiento con agonista de ox40.
|
BR112017009151A2
(pt)
|
2014-11-03 |
2018-03-06 |
Genentech, Inc. |
ensaios para detectar subgrupos imunológicos de célula t e métodos de uso dos mesmos
|
SG11201703376QA
(en)
|
2014-11-06 |
2017-05-30 |
Genentech Inc |
Combination therapy comprising ox40 binding agonists and tigit inhibitors
|
MX2017006320A
(es)
|
2014-11-17 |
2017-08-10 |
Genentech Inc |
Terapia combinada que comprende agonistas de unión de ox40 y antagonistas de unión del eje de pd-1.
|
MA41460A
(fr)
|
2015-02-03 |
2017-12-12 |
Oncomed Pharm Inc |
Agents de liaison à la tnfrsf et leurs utilisations
|
KR20170109582A
(ko)
*
|
2015-02-06 |
2017-09-29 |
히트 바이오로직스, 인코퍼레이티드 |
벡터 공동 발현 백신 및 공동 자극 분자
|
JP6996979B2
(ja)
*
|
2015-03-31 |
2022-02-04 |
エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト |
三量体tnfファミリーリガンドを含む抗原結合分子
|
JP6955445B2
(ja)
|
2015-04-07 |
2021-10-27 |
ジェネンテック, インコーポレイテッド |
アゴニスト性の活性を有する抗原結合複合体及びその使用方法
|
AU2016256911B2
(en)
|
2015-05-07 |
2022-03-31 |
Agenus Inc. |
Anti-OX40 antibodies and methods of use thereof
|
US20160347848A1
(en)
|
2015-05-28 |
2016-12-01 |
Medimmune Limited |
Therapeutic combinations and methods for treating neoplasia
|
US10786547B2
(en)
|
2015-07-16 |
2020-09-29 |
Biokine Therapeutics Ltd. |
Compositions, articles of manufacture and methods for treating cancer
|
PT3317301T
(pt)
|
2015-07-29 |
2021-07-09 |
Novartis Ag |
Terapias de associação compreendendo moléculas de anticorpo contra lag-3
|
US20180207273A1
(en)
|
2015-07-29 |
2018-07-26 |
Novartis Ag |
Combination therapies comprising antibody molecules to tim-3
|
MX2018001787A
(es)
*
|
2015-08-12 |
2018-06-06 |
Medimmune Ltd |
Proteinas de fusion del ligando de la proteina relacionada con el receptor de factor de necrosis tumoral inducido por glucorticoides (gitrl) y usos de las mismas.
|
WO2017046746A1
(en)
|
2015-09-15 |
2017-03-23 |
Acerta Pharma B.V. |
Therapeutic combinations of a btk inhibitor and a gitr binding molecule, a 4-1bb agonist, or an ox40 agonist
|
CA2997955A1
(en)
|
2015-09-15 |
2017-03-23 |
Gilead Sciences, Inc. |
Modulators of toll-like receptors for the treatment of hiv
|
AU2016325610B2
(en)
|
2015-09-25 |
2019-10-10 |
Genentech, Inc. |
Anti-TIGIT antibodies and methods of use
|
AR106188A1
(es)
|
2015-10-01 |
2017-12-20 |
Hoffmann La Roche |
Anticuerpos anti-cd19 humano humanizados y métodos de utilización
|
UA125962C2
(uk)
|
2015-10-02 |
2022-07-20 |
Ф. Хоффманн-Ля Рош Аг |
Біспецифічна антигензв'язуюча молекула до ox40 та фібробласт-активуючого білка (fap)
|
CN108883173B
(zh)
|
2015-12-02 |
2022-09-06 |
阿吉纳斯公司 |
抗体和其使用方法
|
JP2019503349A
(ja)
|
2015-12-17 |
2019-02-07 |
ノバルティス アーゲー |
Pd−1に対する抗体分子およびその使用
|
SG10202108724YA
(en)
|
2016-01-08 |
2021-09-29 |
Replimune Ltd |
Modified oncolytic virus
|
EP3402507A4
(en)
*
|
2016-01-11 |
2019-08-07 |
Inhibrx, Inc. |
MULTIVALENT AND MULTISPECIFIC OX40-BINDING FUSION PROTEINS
|
US11497781B2
(en)
|
2016-03-10 |
2022-11-15 |
Cg Oncology, Inc. |
Methods of treating bladder cancer by combination therapy comprising the oncolytic adenovirus CG0070 and an immune checkpoint inhibitor
|
DE102016105069A1
(de)
|
2016-03-18 |
2017-09-21 |
Eberhard Karls Universität Tübingen Medizinische Fakultät |
Antivirale Immuntherapie durch Membranrezeptorligation
|
EP3231813A1
(en)
*
|
2016-03-29 |
2017-10-18 |
F. Hoffmann-La Roche AG |
Trimeric costimulatory tnf family ligand-containing antigen binding molecules
|
EP3243836A1
(en)
*
|
2016-05-11 |
2017-11-15 |
F. Hoffmann-La Roche AG |
C-terminally fused tnf family ligand trimer-containing antigen binding molecules
|
US11046776B2
(en)
|
2016-08-05 |
2021-06-29 |
Genentech, Inc. |
Multivalent and multiepitopic antibodies having agonistic activity and methods of use
|
CA3040123A1
(en)
|
2016-10-11 |
2018-04-19 |
University Of Miami |
Vectors and vaccine cells for immunity against zika virus
|
TWI788307B
(zh)
|
2016-10-31 |
2023-01-01 |
美商艾歐凡斯生物治療公司 |
用於擴增腫瘤浸潤性淋巴細胞之工程化人造抗原呈現細胞
|
MA46770A
(fr)
|
2016-11-09 |
2019-09-18 |
Agenus Inc |
Anticorps anti-ox40, anticorps anti-gitr, et leurs procédés d'utilisation
|
TW201837168A
(zh)
|
2017-01-06 |
2018-10-16 |
美商艾歐凡斯生物治療公司 |
以腫瘤壞死因子受體超家族(tnfrsf)促效劑使腫瘤浸潤淋巴球(til)擴增及til與tnfrsf促效劑的治療組合
|
CA3058938A1
(en)
|
2017-04-04 |
2018-10-11 |
Heat Biologics, Inc. |
Intratumoral vaccination
|
CN110573624A
(zh)
|
2017-04-14 |
2019-12-13 |
永恒生物科技股份有限公司 |
治疗膀胱癌的方法
|
WO2018226714A1
(en)
|
2017-06-05 |
2018-12-13 |
Iovance Biotherapeutics, Inc. |
Methods of using tumor infiltrating lymphocytes in double-refractory melanoma
|
KR20200100060A
(ko)
|
2017-11-17 |
2020-08-25 |
이오반스 바이오테라퓨틱스, 인크. |
미세 바늘 흡인물 및 소형 생검물로부터의 til 확장
|
BR112020013848A2
(pt)
|
2018-01-08 |
2020-12-01 |
Iovance Biotherapeutics, Inc. |
métodos para expandir linfócitos infiltrantes de tumor e para tratar um indivíduo com câncer, população de linfócitos infiltrantes de tumor, e, método para avaliar fatores de transcrição
|
US11713446B2
(en)
|
2018-01-08 |
2023-08-01 |
Iovance Biotherapeutics, Inc. |
Processes for generating TIL products enriched for tumor antigen-specific T-cells
|
WO2019136459A1
(en)
|
2018-01-08 |
2019-07-11 |
Iovance Biotherapeutics, Inc. |
Processes for generating til products enriched for tumor antigen-specific t-cells
|
MA51875A
(fr)
|
2018-02-13 |
2020-12-23 |
Iovance Biotherapeutics Inc |
Expansion de lymphocytes infiltrant les tumeurs (til) avec des antagonistes du récepteur a2a de l'adénosine et combinaisons thérapeutiques de til et d'antagonistes du récepteur a2a de l'adénosine
|
WO2019184909A1
(zh)
|
2018-03-27 |
2019-10-03 |
信达生物制药(苏州)有限公司 |
新型抗体分子、其制备方法及其用途
|
CN110305210B
(zh)
|
2018-03-27 |
2023-02-28 |
信达生物制药(苏州)有限公司 |
新型抗体分子、其制备方法及其用途
|
MX2020011134A
(es)
|
2018-04-27 |
2020-11-11 |
Iovance Biotherapeutics Inc |
Proceso cerrado para expansion y edicion de genes de linfocitos infiltrantes de tumor y usos de los mismos en inmunoterapia.
|
CN112672758A
(zh)
|
2018-06-25 |
2021-04-16 |
英摩杜伦治疗学公司 |
癌症治疗
|
BR112021002164A2
(pt)
|
2018-08-13 |
2021-08-03 |
Inhibrx, Inc. |
polipeptídeos de ligação a ox40 e usos dos mesmos
|
TW202031273A
(zh)
|
2018-08-31 |
2020-09-01 |
美商艾歐凡斯生物治療公司 |
抗pd-1抗體難治療性之非小細胞肺癌(nsclc)病患的治療
|
WO2020061429A1
(en)
|
2018-09-20 |
2020-03-26 |
Iovance Biotherapeutics, Inc. |
Expansion of tils from cryopreserved tumor samples
|
EP3864049A1
(en)
|
2018-10-11 |
2021-08-18 |
Inhibrx, Inc. |
Pd-1 single domain antibodies and therapeutic compositions thereof
|
JP2022512899A
(ja)
|
2018-11-05 |
2022-02-07 |
アイオバンス バイオセラピューティクス,インコーポレイテッド |
抗pd-1抗体に対して不応性のnsclc患者の治療
|
EP3877512A2
(en)
|
2018-11-05 |
2021-09-15 |
Iovance Biotherapeutics, Inc. |
Selection of improved tumor reactive t-cells
|
US20220033775A1
(en)
|
2018-11-05 |
2022-02-03 |
Iovance Biotherapeutics, Inc. |
Expansion of tils utilizing akt pathways inhibitors
|
PE20211292A1
(es)
|
2018-11-05 |
2021-07-20 |
Iovance Biotherapeutics Inc |
Procesos para la produccion de linfocitos infiltrantes de tumor y usos de estos en inmunoterapia
|
TW202028222A
(zh)
|
2018-11-14 |
2020-08-01 |
美商Ionis製藥公司 |
Foxp3表現之調節劑
|
WO2020131547A1
(en)
|
2018-12-19 |
2020-06-25 |
Iovance Biotherapeutics, Inc. |
Methods of expanding tumor infiltrating lymphocytes using engineered cytokine receptor pairs and uses thereof
|
CA3134144A1
(en)
|
2019-03-29 |
2020-10-08 |
Myst Therapeutics, Llc |
Ex vivo methods for producing a t cell therapeutic and related compositions and methods
|
US20220249559A1
(en)
|
2019-05-13 |
2022-08-11 |
Iovance Biotherapeutics, Inc. |
Methods and compositions for selecting tumor infiltrating lymphocytes and uses of the same in immunotherapy
|
EP4037693A1
(en)
|
2019-09-30 |
2022-08-10 |
Astrazeneca AB |
Combination treatment for cancer
|
US20220389381A1
(en)
|
2019-10-25 |
2022-12-08 |
Iovance Biotherapeutics, Inc. |
Gene editing of tumor infiltrating lymphocytes and uses of same in immunotherapy
|
IL293350A
(en)
|
2019-11-27 |
2022-07-01 |
Myst Therapeutics Llc |
A method for producing tumor-reactive t cells using modulatory substances
|
CA3161104A1
(en)
|
2019-12-11 |
2021-06-17 |
Cecile Chartier-Courtaud |
Processes for the production of tumor infiltrating lymphocytes (tils) and methods of using the same
|
CN115427438A
(zh)
|
2020-02-27 |
2022-12-02 |
迈斯特治疗公司 |
肿瘤反应性t细胞的离体富集和扩增的方法及其相关组合物
|
US20230172987A1
(en)
|
2020-05-04 |
2023-06-08 |
Iovance Biotherapeutics, Inc. |
Processes for production of tumor infiltrating lymphocytes and uses of the same in immunotherapy
|
CA3177413A1
(en)
|
2020-05-04 |
2021-11-11 |
Michelle SIMPSON-ABELSON |
Selection of improved tumor reactive t-cells
|
WO2022076606A1
(en)
|
2020-10-06 |
2022-04-14 |
Iovance Biotherapeutics, Inc. |
Treatment of nsclc patients with tumor infiltrating lymphocyte therapies
|
EP4225330A1
(en)
|
2020-10-06 |
2023-08-16 |
Iovance Biotherapeutics, Inc. |
Treatment of nsclc patients with tumor infiltrating lymphocyte therapies
|
EP4240383A1
(en)
|
2020-11-06 |
2023-09-13 |
Immodulon Therapeutics Limited |
Mycobacterial immunotherapy for treating cancer
|
JP2023551645A
(ja)
|
2020-11-10 |
2023-12-12 |
イモデュロン セラピューティクス リミテッド |
がん治療における使用のためのマイコバクテリウム
|
WO2022125941A1
(en)
|
2020-12-11 |
2022-06-16 |
Iovance Biotherapeutics, Inc. |
Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with braf inhibitors and/or mek inhibitors
|
JP2023554395A
(ja)
|
2020-12-17 |
2023-12-27 |
アイオバンス バイオセラピューティクス,インコーポレイテッド |
Ctla-4及びpd-1阻害剤と併用した腫瘍浸潤リンパ球療法による治療
|
CA3202473A1
(en)
|
2020-12-17 |
2022-06-23 |
Friedrich Graf Finckenstein |
Treatment of cancers with tumor infiltrating lymphocytes
|
WO2022225981A2
(en)
|
2021-04-19 |
2022-10-27 |
Iovance Biotherapeutics, Inc. |
Chimeric costimulatory receptors, chemokine receptors, and the use of same in cellular immunotherapies
|
WO2022261018A1
(en)
|
2021-06-07 |
2022-12-15 |
Providence Health & Services - Oregon |
Cxcr5, pd-1, and icos expressing tumor reactive cd4 t cells and their use
|
WO2023007107A1
(en)
|
2021-07-27 |
2023-02-02 |
Immodulon Therapeutics Limited |
A mycobacterium for use in cancer therapy
|
TW202327631A
(zh)
|
2021-07-28 |
2023-07-16 |
美商艾歐凡斯生物治療公司 |
利用腫瘤浸潤性淋巴球療法與kras抑制劑組合治療癌症患者
|
TW202331735A
(zh)
|
2021-10-27 |
2023-08-01 |
美商艾歐凡斯生物治療公司 |
協調用於患者特異性免疫療法之細胞之製造的系統及方法
|
AU2022388729A1
(en)
|
2021-11-10 |
2024-05-16 |
Iovance Biotherapeutics, Inc. |
Methods of expansion treatment utilizing cd8 tumor infiltrating lymphocytes
|
WO2023147486A1
(en)
|
2022-01-28 |
2023-08-03 |
Iovance Biotherapeutics, Inc. |
Tumor infiltrating lymphocytes engineered to express payloads
|
WO2023201369A1
(en)
|
2022-04-15 |
2023-10-19 |
Iovance Biotherapeutics, Inc. |
Til expansion processes using specific cytokine combinations and/or akti treatment
|
WO2024030758A1
(en)
|
2022-08-01 |
2024-02-08 |
Iovance Biotherapeutics, Inc. |
Chimeric costimulatory receptors, chemokine receptors, and the use of same in cellular immunotherapies
|